Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03298451
Title Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

hepatocellular carcinoma

Therapies

Sorafenib

Durvalumab + Tremelimumab

Durvalumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.